Yuanzeng Min

ADVERTISEMENT RETURN TO ISSUEPREVReviewClinical Translation of NanomedicineYuanzeng Min, Joseph M. Caster, Michael J. Eblan, and Andrew Z. Wang*View Author Information Laboratory of Nano- and Translational Medicine, Carolina Institute of Nanomedicine, Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina—Chapel Hill, Chapel Hill, North Carolina 27599, United States*E-mail: [email protected]. Website: http://www.med.unc.edu/radonc/Wang.Cite this: Chem. Rev. 2015, 115, 19, 11147–11190Publication Date (Web):June 19, 2015Publication History Received24 February 2015Published online19 June 2015Published inissue 14 October 2015https://pubs.acs.org/doi/10.1021/acs.chemrev.5b00116https://doi.org/10.1021/acs.chemrev.5b00116review-articleACS PublicationsCopyright © 2015 American Chemical SocietyRequest reuse permissionsArticle Views10700Altmetric-Citations611LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Antineoplastic agents,Cancer,Cancer therapy,Pharmaceuticals,Toxicity Get e-Alerts

Platinum-based drugs are among the most active antitumor reagents in clinical practice; their application is limited by side effects and drug resistance. A novel and personalized near-infrared (NIR) light-activated nanoplatform is obtained by combining a photoactivatable platinum(IV) prodrug and a caspase imaging peptide conjugated with silica-coated upconversion-luminescent nanoparticles (UCNPs) for the remote control of antitumor platinum prodrug activation, and simultaneously for real-time imaging of apoptosis induced by activated cytotoxicity. Upon NIR light illumination, the Pt(IV) prodrug complex is activated at the surface of the nanoparticle and active components are selectively released which display cytotoxicity against human ovarian carcinoma A2780 cells and its cisplatin-resistant variant A2780cis cells. More importantly, the caspases enzymes triggered by cytotoxicity would effectively cleave the probe peptide, thereby allowing the direct imaging of apoptosis in living cells.

Resistance is futile: A platinum(IV) prodrug conjugated to a gold-nanorod-based delivery agent avoids the type of drug resistance that is associated with cisplatin (see picture). This conjugate is taken up into cells through endocytosis, thus avoiding the resistance-associated uptake mediated by the copper transport protein Ctr1. The platinum(IV) prodrug is more inert than cisplatin to glutathione and metallothionein, which cause deactivation. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.